Table 1 Characteristics of 53 patients receiving 13-cis-retinoic acid at start of re-differentiation therapy

Female, n (%)

34 (64%)

Age at thyroid cancer diagnosis (years), median (range)

57 (15 – 69)

Primary histopathology, n (%)

   papillary

34 (64%)

   follicular

17 (32%)

   insular

2 (4%)

Localization of metastatic disease, n (%)*:

   lung

31 (58%)

   locoregional disease

13 (25%)

   hyperthyroglobulinaemia

8 (15%)

   bones

6 (11%)

   other

5 (9%)

Previous radioiodine treatments

   number, median (range)

2 (0–5)

   cumulative activity – GBq; median (range)

6.66 (0.00–15.54])

Time from thyroid cancer diagnosis to 13-CRA RDT, median (range)

54 (6–186) months